NEW YORK (GenomeWeb) – Alere reported today that its first quarter revenues declined 2 percent year over year as currency translation hit its top line.

The Waltham, Massachusetts-based diagnostics firm reported revenues of $610.4 million for the quarter ended March 31, compared to $625 million for the first quarter of 2014. On average, Wall Street analysts had estimated revenues of $612.9 million.

The Q1 revenues included a negative foreign currency impact of $28.7 million, Alere said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.